Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

Wed, 02 Sep 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference.

Cantor Global Healthcare Conference

Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET

The presentation will premiere at the time listed above and can be accessed by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

Wed, 02 Sep 2026 08:00:00 -0400

Cantor Global Healthcare Conference

Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET

The presentation will premiere at the time listed above and can be accessed by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at

Aligos partner doses first participant in ALG-170675 Phase 1 trial

Wed, 12 Aug 2026 16:05:44 -0400

Aligos Therapeutics (NASDAQ: ALGS) announced that its partner Xiamen Amoytop Biotech Co., Ltd. has dosed the first participant in a Phase 1 study of ALG-170675, an investigational antisense oligonucleotide (ASO) being evaluated for the treatment of chronic hepatitis B virus (HBV) infection. The study is being conducted in China, where Amoytop holds regional rights.

ALG-170675 was discovered by Aligos through a research collaboration with Amoytop. According to the press release, the compound has shown improved RNase H mediated in vivo activity compared to GSK-836 (bepirovirsen), with similar hTLR8 agonist activity observed in vitro and in vivo. The drug candidate also uses

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Wed, 12 Aug 2026 16:05:00 -0400

ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activation
Single and multiple ascending doses planned
Study will allow rapid advancement into participants with chronic HBV infection in Q4 2026

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for functional cure in the treatment of

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Wed, 12 Aug 2026 16:05:00 -0400

ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activation
Single and multiple ascending doses planned
Study will allow rapid advancement into participants with chronic HBV infection in Q4 2026

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Wed, 12 Aug 2026 16:05:00 -0400

ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activation
Single and multiple ascending doses planned
Study will allow rapid advancement into participants with chronic HBV infection in Q4 2026

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Wed, 12 Aug 2026 16:05:00 -0400

ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activation
Single and multiple ascending doses planned
Study will allow rapid advancement into participants with chronic HBV infection in Q4 2026

H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)

Mon, 10 Aug 2026 06:49:45 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $50.00 price target on Aligos Therapeutics Inc. (NASDAQ: ALGS).

The analyst commented: "On August 6, Aligos reported 2Q26 results and recent business progress centered on chronic hepatitis B virus (HBV) infection. Pevifoscorvir sodium (pevy; formerly ALG-000184) received breakthrough therapy designation from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), adding to the FDA fast track designation granted in April 2026. Additionally, Aligos announced complete enrollment of the Phase 2 B-SUPREME trial, with 131 participants in the HBeAg+ Part 1a and 114 in the HBeAg- Part 2a,

Form S-8 Aligos Therapeutics,

Thu, 06 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26883550.html

Form S-8 Aligos Therapeutics,

Thu, 06 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26883550.html

Aligos Therapeutics Inc. (ALGS) Tops Q2 EPS by 101c

Thu, 06 Aug 2026 08:46:24 -0400

Aligos Therapeutics Inc. (NASDAQ: ALGS) reported Q2 EPS of ($0.14), $1.01 better than the analyst estimate of ($1.15).

For earnings history and earnings-related data on Aligos Therapeutics Inc. (ALGS) click here.

Form 10-Q Aligos Therapeutics, For: Jun 30

Thu, 06 Aug 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26879414.html

Form 10-Q Aligos Therapeutics, For: Jun 30

Thu, 06 Aug 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26879414.html

Form 8-K Aligos Therapeutics, For: Aug 06

Thu, 06 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26879264.html

Form 8-K Aligos Therapeutics, For: Aug 06

Thu, 06 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26879264.html

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2026.

“Our team has continued to execute on our key strategic priorities to advance our pipeline this year,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “We strengthened our financial position through non-dilutive capital, including the $25M upfront payment related to the exclusive Greater China

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 08:00:00 -0400

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Thu, 30 Jul 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s second quarter 2026 financial results on Thursday, August 6, 2026, before the open of the U.S. financial markets.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Thu, 30 Jul 2026 08:00:00 -0400

About Aligos

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Thu, 30 Jul 2026 08:00:00 -0400

About Aligos

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Thu, 30 Jul 2026 08:00:00 -0400

About Aligos

H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)

Tue, 14 Jul 2026 07:04:47 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $50.00 price target on Aligos Therapeutics Inc. (NASDAQ: ALGS).

The analyst commented: "On July 13, Aligos announced completion of enrollment in the Phase 2 trial (B-SUPREME) evaluating pevifoscorvir sodium (pevy; formerly ALG-000184) vs tenofovir disoproxil fumarate (TDF) in chronic hepatitis B virus (HBV) infection. In our follow-up call with Aligos, management confirmed that all 245 participants—131 hepatitis B e antigen (HBeAg)-positive and 114 HBeAg-negative—are included in the primary efficacy cohorts, while the paired-biopsy cohorts are separate. The HBeAg-negative cohort exceeded its 100-patient target because a surge of already-in-screening patients qualified after

Aligos completes enrollment in phase 2 HBV drug study

Mon, 13 Jul 2026 08:00:17 -0400

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the completion of enrollment in its Phase 2 B-SUPREME study evaluating pevifoscorvir sodium for the treatment of chronic hepatitis B virus (HBV) infection, according to a press release from the South San Francisco-based company.

The study enrolled 131 HBeAg+ participants in Part 1a and 114 HBeAg- participants in Part 2a. Because Part 1a exceeded its planned enrollment target, a second interim analysis for sample size re-estimation will not be conducted. Topline safety and efficacy data are expected in late third quarter of 2027.

The B-SUPREME study (NCT06963710) is a randomized, double-blind, active-controlled multicenter trial comparing pevifoscorvir

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Mon, 13 Jul 2026 08:00:00 -0400

Topline data expected to be available late 3Q2027

SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment of both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in the Phase 2 B-SUPREME study of pevifoscorvir sodium, under development for the treatment of chronic hepatitis B virus (HBV) infection. Topline safety and efficacy data are expected to be available in late third quarter of 2027.

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Mon, 13 Jul 2026 08:00:00 -0400

Topline data expected to be available late 3Q2027

StreetInsider.com News Articles

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

Aligos partner doses first participant in ALG-170675 Phase 1 trial

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)

Form S-8 Aligos Therapeutics,

Form S-8 Aligos Therapeutics,

Aligos Therapeutics Inc. (ALGS) Tops Q2 EPS by 101c

Form 10-Q Aligos Therapeutics, For: Jun 30

Form 10-Q Aligos Therapeutics, For: Jun 30

Form 8-K Aligos Therapeutics, For: Aug 06

Form 8-K Aligos Therapeutics, For: Aug 06

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)

Aligos completes enrollment in phase 2 HBV drug study

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection